Provell Pharmaceuticals, LLC

Note: Provell Pharma ceased operations in March 2025. This page remains active as an archive of our accomplishments, partnerships, and contributions to the pharmaceutical industry. Founded in 2005, Provell Pharma specialized in the marketing and distribution of leading pharmaceutical products in the U.S., with a focus on endocrine therapies—particularly thyroid hormone replacement. Our mission was to deliver innovative pharmaceutical solutions that improved drug quality and stability, enhanced patient adherence, and reduced cost. In September 2018, Provell successfully launched EUTHYROX® in the U.S. market through an exclusive partnership with one of the world's oldest healthcare companies. As a branded drug priced in line with generics, EUTHYROX® improved access and price transparency for both physicians and patients. Within the first two years, it reached over 1.2 million patients and 100,000 prescribing physicians, including a top 3 U.S. retail account. We are proud of our legacy and grateful for the teams, partners, and clients who made it possible. Thank you.